Quality of life among lung cancer patients undergoing treatment at a tertiary cancer institute in North India

Barwal, Vijay Kumar; Mazta, Salig Ram; Thakur, Anita; Seam, Rajeev Kumar; Gupta, Manish

doi:10.18203/2320-6012.ijrms20163789

Cited by 5 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding assessment of symptom response, in 1 month significant improvement of all the symptoms in both the arms was evidenced that is similar to the studies by Barwal KV et al [25] and Langendijk et al [26].…”

Section: Symptomatic Response Post Treatmentsupporting

confidence: 88%

Comparative Study of Concurrent Chemoradiation Using Paclitaxel in Two Histopathological Subtypes (Squamous Cell Carcinoma/Adenocarcinoma) of Unresectable Non-Small Cell Lung Cancer

Nongrum¹,

Devi

Mohanty

et al. 2022

IJMMR

View full text Add to dashboard Cite

Background. Lung cancer is still a global burden and with rising population and increasing life expectancy the incidence of lung cancer is still on the rise. Objective. To compare the treatment response and toxicity of weekly paclitaxel in locally advanced unresectable non-small cell lung cancer (NSCLC), when administered concurrently with external beam radiation to the chest in two different histopathological types – adenocarcinoma and squamous cell carcinoma. Methods. A prospective randomised control trial was conducted in 60 NSCLC patients who were divided into two arms; adenocarcinoma and squamous cell carcinoma arm. All patients were treated with chemoradiation with concurrent paclitaxel 60 mg/m2. Data were evaluated with SPSS version 21.0 for windows with p-value <0.05. Results. Haematological toxicity was the most common side effects evident from the third week of chemotherapy. At the end of 1 month of treatment, two (6.7%) patients had complete response in Arm A and one (3.3%) patient had complete response in Arm B. One (3.3%) patient had disease progression in Arm A and two patients progressed in Arm B. At 7 months post treatment three (10%) patients had complete response in both Arm A and Arm B. Four (13.3%) patients had disease progression in Arm A and ten (33.4%) patients progressed in Arm B. Conclusions. Paclitaxel can be used as an alternative chemotherapeutic agent to the standard cisplatin. However, further studies with larger sample size are required to confirm the findings.

show abstract

Section: Symptomatic Response Post Treatmentsupporting

confidence: 88%

Comparative Study of Concurrent Chemoradiation Using Paclitaxel in Two Histopathological Subtypes (Squamous Cell Carcinoma/Adenocarcinoma) of Unresectable Non-Small Cell Lung Cancer

Nongrum¹,

Devi

Mohanty

et al. 2022

IJMMR

View full text Add to dashboard Cite

show abstract

“…26 Another study in North India concluded that there is a decline in the global QOL and social functioning in lung cancer patients following treatment. 27 Similarly in this study, mean overall QOL was 44.55 (maximum possible score was 108 and interpreted as higher the score, higher the QOL). It indicates that cancer patients experience fatigue during and followed by treatment and it declines the QOL of patients that needs preventive strategies to overcome.…”

Section: Discussionsupporting

confidence: 64%

Effect of Multimodal Intervention on Cancer-Related Fatigue and Quality of Life among Patients Undergoing Cancer Treatment—Pilot Study (Part 1)

Shambhavi

Lobo²

2023

Journal of Health and Allied Sciences NU

View full text Add to dashboard Cite

Background Cancer-related fatigue (CRF) is the most common and devastating problem in cancer patients even after successful treatment. CRF has a severe impact on daily activities, social relationships, reintegration, and overall quality of life (QOL). Objective This study was done to evaluate the effect of multimodal intervention (MMI) on CRF and QOL among cancer patients undergoing cancer treatment. Materials and Methods One group before-and-after study (pre-experimental design) was conducted among cancer patients undergoing cancer treatment who met inclusion criteria and were selected using a purposive sampling technique, in selected hospitals. MMI consisted of exercise program, acupressure, and home care management guide. Pre-test CRF and QOL were assessed on first day using a FACIT-F scale (Functional Assessment of Chronic Illness Therapy: Fatigue) and Functional Assessment of Cancer Therapy: Fatigue (FACT-G) Version 4, respectively. Post- test for CRF was further determined after 7 days, 21 days, and 3months and QOL was determined after 21 days and 3 months. Statistical Analysis Demographic and clinical characteristics of the participants are presented as frequency and percentage. Comparison of pre- test and post-test means of CRF and QOL is done by repeated measures analysis of variance (ANOVA). Correlation between fatigue and QOL of cancer patients was found by using Pearson correlation test. Results The mean pre-test fatigue score of the cancer patients (pre-test mean= 25.21) was lower than their mean post-test fatigue scores (post-test 1 =25.83, post-test 2 = 28.28, and post-test 3 = 34.72). There was a significant difference in CRF and QOL scores between before and after the MMI. In the repeated measures ANOVA, p-value is less than 0.05 (level of significance p < 0.05). Conclusion Regardless of mechanism of occurrence of fatigue, most patients living with cancer suffer with persistent CRF. Yet it is often not assessed, has limited treatment options, there is a need to assess the state of fatigue in cancer patients. They do need intervention to reduce the fatigue and to improve the QOL. Nonpharmacological therapies are the best strategies to manage the fatigue among cancer patients without any safety issue.

show abstract

“…A study by Sharma et al(2017) in Delhi concluded that there is association between clinical, sociodemographic characteristics, and QoL of breast cancer patients 21 . Another study by Barwal et al (2016) in North India concluded that there is a decline in the global QoL and social functioning in lung cancer patients following treatment 22 …”

Section: Introductionmentioning

confidence: 99%

“… 21 Another study by Barwal et al (2016) in North India concluded that there is a decline in the global QoL and social functioning in lung cancer patients following treatment. 22 …”

Section: Introductionmentioning

confidence: 99%

Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital

et al. 2020

View full text Add to dashboard Cite

Background Cancer is the second most common cause of deaths worldwide. Likewise, in India, it is a major health problem, and disease burden is escalating every year. Cancer chemotherapy produces unfavorable effects on the well‐being of an individual. Since the past few years, quality of life (QoL) is considered as the main goal of cancer treatment in the survival of a patient. Aim This current study aimed to assess the QoL and factors affecting it in adult cancer patients undergoing chemotherapy treatment. Methods and Results An analytical, cross‐sectional study was conducted to achieve the objectives, employing the consecutive sampling method. A total of 120 adult (>19 years) patients were recruited from daycare chemotherapy unit of a tertiary care hospital. The data were collected using patient record form and Functional Assessment of Cancer Therapy‐General (FACT‐G), a quality of life (QoL) questionnaire. The overall mean score of quality of life (QoL) was 61.933 ± 5.85502. The domains of functional well‐being and emotional well‐being were most negatively affected after cancer chemotherapy. Education (illiteracy) and occupation (unemployment) were negatively associated with overall quality of life (QoL) of cancer patients on chemotherapy. Adverse drug reactions due to cancer chemotherapy negatively affect the quality of life (QoL) of cancer patients. Education (illiteracy) affects social well‐being domain of cancer patients. Working in the government/private sector has a positive impact on functional well‐being domain of quality of life (QoL). Conclusion The study findings suggest an overall low quality of life (QoL) among adult cancer patients undergoing chemotherapy at our setup. It has been identified as a stressful therapy, also affecting both psychological and physical well‐being. Poor infrastructure, illiteracy, poverty, and lack of proper treatment facilities at most centres often lead to poor survival outcomes and hence focus has always been on achieving quantity of life rather than quality of life (QoL). This is further complicated due to nonavailability of validated tools in local vernacular, apathy of the treating physicians in the context of QoL aspects and social and cultural factors that are unique to this society. Psycho‐oncology needs to become an integral entity of comprehensive cancer care.

show abstract

Quality of life among lung cancer patients undergoing treatment at a tertiary cancer institute in North India

Cited by 5 publications

References 17 publications

Comparative Study of Concurrent Chemoradiation Using Paclitaxel in Two Histopathological Subtypes (Squamous Cell Carcinoma/Adenocarcinoma) of Unresectable Non-Small Cell Lung Cancer

Comparative Study of Concurrent Chemoradiation Using Paclitaxel in Two Histopathological Subtypes (Squamous Cell Carcinoma/Adenocarcinoma) of Unresectable Non-Small Cell Lung Cancer

Effect of Multimodal Intervention on Cancer-Related Fatigue and Quality of Life among Patients Undergoing Cancer Treatment—Pilot Study (Part 1)

Quality of life and factors affecting it in adult cancer patients undergoing cancer chemotherapy in a tertiary care hospital

Contact Info

Product

Resources

About